Effectiveness of Physical Teraphy in the Treatment of Myogenic Temporomandibular Disorders
Launched by PAOLO PILLASTRINI · Oct 30, 2018
Trial Information
Current as of May 13, 2025
Completed
Keywords
ClinConnect Summary
Randomized controlled clinical trial with randomization according to a multi-phase design.
Phase 1 involves the enrollment of patients with DTMs based on diagnostic criteria.
Phase 2 includes the algogenic, kinetic and gnathological evaluation of the enrolled patients.
Phase 3 provides for the adoption of the criterion to one of the 2 treatment groups on the basis of the randomization list.
The 2 therapeutic protocols are:
* gnathological therapy (splint) associated with education and physiotherapy (test group);
* gnathological therapy (splint) associated with education (control group)...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • patients with myogenic temporomandibular disorders assessed with clinical examination as established by the DC / TMD1;
- • patients older than 18 years;
- • good knowledge of Italian language;
- • patients who have signed informed consent
- Exclusion Criteria:
- • edentulism which makes it impossible to apply gnathological bite;
- • patients with psychiatric problems;
- • patients included in other experimental protocols;
- • patients already undergoing surgical and / or radial therapy of the cervical and facial areas;
- • other temporomandibular disorders without a myogenic component;
- • treatment of the cervical and TMJ district in the previous 3 months;
- • history of drug abuse.
About Paolo Pillastrini
Paolo Pillastrini is a distinguished clinical trial sponsor dedicated to advancing medical research and innovation. With a strong emphasis on ethical standards and patient safety, the organization collaborates with leading healthcare professionals and institutions to conduct rigorous clinical trials across various therapeutic areas. Committed to transparency and scientific integrity, Paolo Pillastrini leverages cutting-edge methodologies and technologies to facilitate the development of new treatments and improve patient outcomes. Their expertise in trial design and management ensures high-quality data and compliance with regulatory requirements, contributing to the advancement of healthcare solutions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Bologna, Emilia Romagna, Italy
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials